PDF(Pubmed)
Abstract：
UNASSIGNED: A common treatment strategy for individuals with multifocal hepatocellular carcinoma (HCC) who are not candidates for surgical resection is transarterial chemoembolization (TACE). Combining TACE with 125I seed insertion (ISI) may offer a means of enhancing therapeutic efficacy. The purpose of this study was to compare the therapeutic efficacy of TACE administered with and without ISI for the treatment of multifocal HCC.
UNASSIGNED: The data from the two centers were analyzed retrospectively. The present study involved 85 consecutive patients with multifocal HCC who underwent TACE between January 2018 and December 2021. Of these patients, 43 were in the combined group, receiving TACE with ISI, and 42 were in the TACE-only group, receiving TACE without ISI. Comparisons of treatment outcomes were made between these groups.
UNASSIGNED: No significant differences in baseline data were observed between these groups of patients. Higher rates of complete (60.5% vs. 33.3%, P = 0.016) and total (93.0% vs. 61.9%, P = 0.001) responses were evident in the combined group compared to the TACE-only group. Median progression-free survival (PFS, 13 vs. 10 months, P = 0.014) and overall survival (OS, 22 vs. 17 months, P = 0.035) were also significantly longer in the combined group than in the TACE-only group. Using a Cox regression analysis, risk variables associated with shorter PFS and OS included Child-Pugh B status (P = 0.027 and 0.004) and only TACE treatment (P = 0.011 and 0.022).
UNASSIGNED: In summary, these findings suggest that, as compared to TACE alone, combining TACE and ISI can enhance HCC patients\' treatment outcomes and survival.
UNASSIGNED: The data from the two centers were analyzed retrospectively. The present study involved 85 consecutive patients with multifocal HCC who underwent TACE between January 2018 and December 2021. Of these patients, 43 were in the combined group, receiving TACE with ISI, and 42 were in the TACE-only group, receiving TACE without ISI. Comparisons of treatment outcomes were made between these groups.
UNASSIGNED: No significant differences in baseline data were observed between these groups of patients. Higher rates of complete (60.5% vs. 33.3%, P = 0.016) and total (93.0% vs. 61.9%, P = 0.001) responses were evident in the combined group compared to the TACE-only group. Median progression-free survival (PFS, 13 vs. 10 months, P = 0.014) and overall survival (OS, 22 vs. 17 months, P = 0.035) were also significantly longer in the combined group than in the TACE-only group. Using a Cox regression analysis, risk variables associated with shorter PFS and OS included Child-Pugh B status (P = 0.027 and 0.004) and only TACE treatment (P = 0.011 and 0.022).
UNASSIGNED: In summary, these findings suggest that, as compared to TACE alone, combining TACE and ISI can enhance HCC patients\' treatment outcomes and survival.
摘要：
■对于不适合手术切除的多灶性肝细胞癌（HCC）患者的常见治疗策略是经动脉化疗栓塞（TACE）。将TACE与125I种子插入(ISI)组合可以提供增强治疗功效的手段。这项研究的目的是比较有和没有ISI的TACE治疗多灶性HCC的疗效。
■对两个中心的数据进行了回顾性分析。本研究涉及2018年1月至2021年12月期间接受TACE的85例多灶性HCC连续患者。在这些病人中,43人在联合组，接收与ISI的TACE，只有42人属于TACE组，接收没有ISI的TACE。比较这些组之间的治疗结果。
■在这些患者组之间没有观察到基线数据的显着差异。更高的完成率（60.5%与33.3%,P=0.016）和总计（93.0%vs.61.9%,与仅TACE组相比，联合组的P=0.001）反应明显。中位无进展生存期(PFS，13vs.10个月,P=0.014)和总生存率(OS，22vs.17个月,联合组的P=0.035）也明显长于仅TACE组。使用Cox回归分析，与较短PFS和OS相关的风险变量包括Child-PughB状态(P=0.027和0.004)和仅TACE治疗(P=0.011和0.022).
■总之，这些发现表明，与单独的TACE相比，联合TACE和ISI可以提高HCC患者的治疗结果和生存率。
■对两个中心的数据进行了回顾性分析。本研究涉及2018年1月至2021年12月期间接受TACE的85例多灶性HCC连续患者。在这些病人中,43人在联合组，接收与ISI的TACE，只有42人属于TACE组，接收没有ISI的TACE。比较这些组之间的治疗结果。
■在这些患者组之间没有观察到基线数据的显着差异。更高的完成率（60.5%与33.3%,P=0.016）和总计（93.0%vs.61.9%,与仅TACE组相比，联合组的P=0.001）反应明显。中位无进展生存期(PFS，13vs.10个月,P=0.014)和总生存率(OS，22vs.17个月,联合组的P=0.035）也明显长于仅TACE组。使用Cox回归分析，与较短PFS和OS相关的风险变量包括Child-PughB状态(P=0.027和0.004)和仅TACE治疗(P=0.011和0.022).
■总之，这些发现表明，与单独的TACE相比，联合TACE和ISI可以提高HCC患者的治疗结果和生存率。
